Compare
Amgen vs Arcus Biosciences (AMGN vs RCUS)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year Amgen (AMGN) returned +43.9% and Arcus Biosciences (RCUS) -7.4%; so far this year the figures are +40.7% and -23.3%.
Amgen is the larger company by market value, about 94.7 times the size of Arcus Biosciences.
Revenue grew +8.2% at AMGN and +20.0% at RCUS over the last year.
AMGN yields 2.16%. RCUS pays no dividend.
Data as of the latest close. Not investment advice.
Relative performance
| AMGN | RCUS | |
|---|---|---|
| Price | $460.42 | $18.28 |
| 1-day | +0.03% | +3.34% |
| YTD | +40.67% | -23.29% |
| 1 year | +43.94% | -7.44% |
| 3 years | +76.51% | +15.55% |
| Market cap | $249.1B | $2.6B |
| P/E | 26.7 | — |
| P/S | 6.40 | 48.74 |
| P/B | 17.35 | 7.35 |
| Revenue growth | +8.20% | +20.00% |
| EPS growth | +33.30% | — |
| Gross margin % | 70.9 | — |
| Net margin % | 24.1 | -838.9 |
| ROE % | 65.4 | -126.5 |
| Debt / equity | 3.76 | 0.28 |
| FCF yield % | 3.8 | -17.7 |
| Dividend yield % | 2.16 | — |
| Beta | 0.50 | 1.54 |
| RSI (14) | 60.5 | 37.0 |
| Technical rating |